Volume 19, Number 6—June 2013
Zoonotic Mycobacterium bovis–induced Tuberculosis in Humans
Highlight and copy the desired format.
|EID||Müller B, Dürr S, Alonso S, Hattendorf J, Laisse C, Parsons S, et al. Zoonotic Mycobacterium bovis–induced Tuberculosis in Humans. Emerg Infect Dis. 2013;19(6):899-908. https://dx.doi.org/10.3201/eid1906.120543|
|AMA||Müller B, Dürr S, Alonso S, et al. Zoonotic Mycobacterium bovis–induced Tuberculosis in Humans. Emerging Infectious Diseases. 2013;19(6):899-908. doi:10.3201/eid1906.120543.|
|APA||Müller, B., Dürr, S., Alonso, S., Hattendorf, J., Laisse, C., Parsons, S....Zinsstag, J. (2013). Zoonotic Mycobacterium bovis–induced Tuberculosis in Humans. Emerging Infectious Diseases, 19(6), 899-908. https://dx.doi.org/10.3201/eid1906.120543.|
We aimed to estimate the global occurrence of zoonotic tuberculosis (TB) caused by Mycobacterium bovis or M. caprae infections in humans by performing a multilingual, systematic review and analysis of relevant scientific literature of the last 2 decades. Although information from many parts of the world was not available, data from 61 countries suggested a low global disease incidence. In regions outside Africa included in this study, overall median proportions of zoonotic TB of ≤1.4% in connection with overall TB incidence rates ≤71/100,000 population/year suggested low incidence rates. For countries of Africa included in the study, we multiplied the observed median proportion of zoonotic TB cases of 2.8% with the continental average overall TB incidence rate of 264/100,000 population/year, which resulted in a crude estimate of 7 zoonotic TB cases/100,000 population/year. These generally low incidence rates notwithstanding, available data indicated substantial consequences of this disease for some population groups and settings.
Tuberculosis (TB) is among the most devastating human infectious diseases worldwide. An estimated 8.8 million new cases, a global average incidence rate of 128/100,000 population/year, and 1.5 million deaths were attributed to TB in 2010 (1). Human TB is caused principally by M. tuberculosis. The main causative agents of bovine \TB are M. bovis and, to a lesser extent, M. caprae; however, zoonotic transmission of these pathogens is well described and occurs primarily through close contact with infected cattle or consumption of contaminated animal products such as unpasteurized milk (2,3). TB cases caused by transmission of other mycobacteria from other animal reservoirs (e.g., wildlife) have been anecdotally reported (4,5). Globally, most cases of zoonotic TB are caused by M. bovis, and cattle are the major reservoir (2,3). Therefore, for the purpose of this study and the remainder of this report, we refer to zoonotic TB as TB in humans caused by M. bovis or M. caprae.
There is evidence to suggest that zoonotic TB accounted for a significant proportion of the TB cases in the Western world before the introduction of regular milk pasteurization programs (6,7). Currently, in high-income countries, bovine TB is well controlled or eliminated in most areas, and cases of zoonotic TB are rarely seen (6,7). However, reservoirs of TB in wildlife populations have been linked to the persistence or increase of the incidence of bovine TB in some countries, most notably the United Kingdom (UK) (6). The absence of zoonotic TB despite an upsurge in the incidence of bovine TB in the United Kingdom sparked a controversy over the large financial expenditures for disease control in cattle (6).
The situation may be fundamentally different in other regions. For example, in most countries in Africa, bovine TB is prevalent, but effective disease control, including regular milk pasteurization and slaughterhouse meat inspection, is largely absent (2,3). This situation is exacerbated by the presence of multiple additional risk factors such as human behavior and the high prevalence of HIV infections (2,3,7). Although HIV/AIDS is thought to facilitate transmission and progression to active disease of any form of TB, some studies showed a significantly increased proportion of M. bovis infections among HIV–co-infected TB patients compared with HIV-negative TB patients (8–12).
No assessment of the global consequences of zoonotic TB has yet been done. This may have been partially caused by the difficulty of differentiating TB caused by M. tuberculosis or M. bovis, which requires mycobacterial culture and the subsequent use of biochemical or molecular (e.g., genotyping) diagnostic methods. Therefore, in low-income countries, facilities to identify the causative agent of TB are largely absent (2,3,7). A previous comprehensive review on zoonotic TB was published 15 years ago with inferences based primarily on the presence of risk factors rather than the occurrence of actual cases (2). Since then, several studies of zoonotic TB in different parts of the world have been published, enabling a more detailed evaluation of the current importance of the disease. The current study was mandated by the World Health Organization (WHO) Foodborne Disease Burden Epidemiology Reference Group with the aim to determine, on the basis of previously published literature, the global occurrence of zoonotic TB and its contribution to the overall TB prevalence in affected settings.
A systematic multilingual literature search was performed according to international guidelines with certain modifications (http://www.cochrane-handbook.org/). Potentially relevant reports on putative zoonotic TB caused by M. bovis or M. caprae were identified by a search of 32 bibliographic databases by using a highly sensitive search syntax. All publications/reports documented in the various databases and published until March 2010 were considered (Table 1; Technical Appendix 1, 2 [PDF - 233 KB - 4 pages]). Reference Manager v11.0.1 bibliographic software was used to store and remove duplicated reports, leaving 12,176 records (Figure 1). Titles and abstracts of these reports were screened to remove studies unlikely to contain pertinent information. Altogether, 1,203 potentially relevant reports were identified (Technical Appendix 1, 2 [PDF - 233 KB - 4 pages]) of which 447 (37%) were available online and assessed for eligibility (Figure 1).
Eligible records (written in English, French, German, Spanish, or Portuguese) reported data for at least 50 persons tested on the frequency (prevalence, incidence) or death rate of putative zoonotic TB and contained data from no earlier than 1990. In connection with other ongoing studies, records reporting information on disease sequelae and transmission routes were also included. For 100 randomly selected reports of the 1,203 potentially relevant reports, availability and eligibility was assessed independently by 3 operators. Differently appraised records were reassessed, and the screening procedure was harmonized accordingly. The remaining records were randomly assigned to 1 of the 3 individual operators for further assessment; 140 records were considered eligible and subjected to data extraction. The data were stratified by multiple variables, if possible (e.g., country or province, HIV status). If any of the reports included referred to relevant external data or eligible reports that were not identified during the earlier steps of our literature search, the respective data were also included in this analysis. For 15 randomly selected reports of the 140 eligible records and additional data cited by or referring to these records, data extraction was performed independently by the 3 operators. Differently extracted data was reassessed and the extraction procedure was harmonized accordingly. The remaining records were randomly assigned to one of the 3 operators for data extraction. Of 140 eligible records, 91 reported or referred to data on disease frequency or mortality rates of putative zoonotic TB (Technical Appendix 1 [PDF - 233 KB - 4 pages] Figure 2). If accessible, additional population estimates and official TB notifications were included in the database. This core dataset was used to analyze, by geographic region and country, the global occurrence of zoonotic TB in humans and its contribution to the overall TB prevalence in affected settings. A subset of data stratified by HIV status was used to assess a potential association between TB caused by M. bovis and HIV co-infection. For each of these analyses, duplicated data, present in >1 report was removed from the core dataset (Figure 1). Statistical analyses were performed in IC Stata 10.0 (StataCorp LP, College Station, TX, USA).
Data obtained from eligible reports covered 5 of 6 WHO regions (Table 2; Technical Appendix 1 [PDF - 233 KB - 4 pages] Table 3, Figure 1), namely Africa, the Americas, Europe, the Eastern Mediterranean and the Western Pacific. No data were obtained for any country in Southeast Asia. With the exception of Europe, data were acquired for only a few countries of the regions represented in this analysis (Technical Appendix 1 [PDF - 233 KB - 4 pages] Table 1). Notably, for the Eastern Mediterranean and the Western Pacific regions, respectively, data from only 2 and 3 countries were obtained. The considerable lack of data precluded a credible estimation of the global prevalence and incidence of zoonotic TB.
Zoonotic TB in Africa
Among all studies included from Africa, a median of 2.8% (range 0%–37.7%) of all TB cases in humans were caused by M. bovis (Figure 2). In 10 of the 13 countries in Africa included in this study, median proportions of TB caused by M. bovis were below 3.5% and in 5 of these countries no cases were detected (Table 2; Figure 3). In contrast, for Ethiopia, Nigeria and Tanzania, respectively, the median proportion of TB cases caused by M. bovis was 17.0% (range: 16.7%–31.4%) (13–15), 15.4% (1 study available) (16) and 26.1% (range 10.8%–37.7%) (17–19). Percentages of ≈30% were reported in 4 regionally based studies in Tanzania and Ethiopia (Figure 3, Table 2) (13,17). However, many of these studies showed a low sample size, resulting in a high statistical error (Table 2). The lack of large-scale, population-based data did not allow for an identification of specific risk groups associated with M. bovis infections.
Zoonotic TB in the Americas
A median of 0.3% (range 0%–33.9%) of M. bovis infections among human TB cases was found for all reports included. For most countries, M. bovis accounted for a negligible percentage of the TB cases (Figure 2). Conversely, high proportions were reported for specific areas of Mexico and the United States (Figure 4). For Mexico, the median percentage of M. bovis cases was 7.6% (range 0%–31.6%); proportions >10% were detected in 3 independent studies (20–22). However, overall TB incidence in Mexico is relatively low, with a rate of 16/100,000 population/year (1). In the United States, TB caused by M. bovis is strongly linked to persons in Hispanic communities, mostly with origins in Mexico (Table 3). A study including data from 41 states of the United States suggested that ≈90% of all TB cases caused by M. bovis affect persons of Hispanic ethnicity (8). This association is attributed to the consumption of unpasteurized, contaminated cheese produced in Mexico. Moreover, when multivariate logistic regression analyses was used, several studies in the United States showed an independent association of TB caused by M. bovis with TB cases in children, HIV coinfection and extrapulmonary disease (8–12). Surveys in San Diego County, California indicated a steady increase in the incidence of TB caused by M. bovis and a decrease in TB incidence caused by M. tuberculosis infection (9,12). In this setting, the odds for TB patients infected with M. bovis to die during treatment was >2 times as high as for patients infected with M. tuberculosis (9,10,12). In San Diego County, during 1994–2003 and 2001–2005, respectively, M. bovis accounted for 25 and 19 deaths, corresponding to 27% and 17% of all TB deaths and a mortality rate of ≈0.1/100,000 population/year (9,10). The reasons for increased deaths among patients infected with zoonotic TB compared with those infected with M. tuberculosis remained unidentified, although health care inequality or treatment differences were stated as possible explanations (9). However, overall incidence rates of zoonotic TB in the United States are low, at a median of 0.7/100,000 population/year. Although zoonotic TB causes minor consequences of disease in the Americas, available data corroborate the finding that M. bovis infections can be a substantial cause of deaths from TB among humans in certain population groups and settings.
Zoonotic TB in Europe
Studies from Austria, Germany, Greece, and Spain included in this analysis identified M. caprae as a causative agent of zoonotic TB in addition to M. bovis (23–26). Our analysis revealed a median proportion of 0.4% (range 0%–21.1%) of M. bovis or M. caprae infections among all bacteriologically confirmed TB cases reported. Median proportions for individual countries never reached rates >2.3%, although higher percentages were found for specific populations and settings (Figure 5). Three of 5 studies reporting proportions >10% were conducted in settings with very low incidences of human TB (<20 cases/year on a countrywide level) (27). In another hospital-based study in Germany, 4 M. bovis cases were identified among 19 TB cases with molecular speciation results, 2 of which probably represented disease caused by the treatment of urothelial carcinoma with M. bovis BCG (28). A study in Spain characterized the transmission of a multidrug-resistant strain of M. bovis as the cause of 2 nosocomial TB outbreaks that accounted for 12.2% of multidrug-resistant TB isolates (29). However, these cases did not represent cases of zoonotic TB, because transmission occurred from humans to humans. Reported incidence rates for TB caused by M. bovis or M. caprae for all studies included from European countries were <1/100,000 population/year if TB cases caused by multidrug-resistant strains of M. bovis in Spain were excluded (Technical Appendix 2 [PDF - 233 KB - 4 pages]). Moreover, available data suggested decreasing trends in the number of zoonotic TB cases over time (Technical Appendix 2 [PDF - 233 KB - 4 pages]).
Zoonotic TB in the Eastern Mediterranean
One study from the Suez Canal region of Egypt reported a rate of 2.2% (95% CI 0.1%–11.8%) for pulmonary TB cases caused by M. bovis (30). A second nationwide study in Djibouti detected 0.6% (95% CI 0.0%–3.5%) of the TB lymphadenitis cases for which samples were tested to be caused by M. bovis (31). No other studies were obtained for the WHO region of the Eastern Mediterranean. The proportion of zoonotic TB among all TB cases in the eastern Mediterranean is shown in Figure 6.
Zoonotic TB in the Western Pacific
Data obtained from the Western Pacific region was from Australia, New Zealand, and parts of China only. For these settings, respectively, median proportions of M. bovis infections of 0.2% (range 0.1%–0.7%), 2.7% (range 2.4%–5%) and 0.2% (range 0%–0.5%) among all TB cases analyzed were observed, indicating that zoonotic TB had minor importance Median incidence rates were 0.03 (range 0.00–0.60) and 0.16 (range 0.11–0.27)/100,000 population/year for Australia and New Zealand, respectively. The infrequent occurrence of zoonotic TB in these settings notwithstanding, New Zealand showed a generally higher proportion and incidence rate for TB caused by M. bovis than did Australia (Figure 6). While a steadily increasing proportion of TB caused by M. bovis was observed in New Zealand, trends were decreasing in Australia (Technical Appendix 2 [PDF - 233 KB - 4 pages]).
Influence of HIV Co-infection
Seven surveys covering Ethiopia, Tanzania, Argentina, Mexico, and different parts of the United States provided data for analysis of a potential association between HIV co-infection and zoonotic TB (Table 4) (8–10,13,18,20,32). Among these studies, only studies from the United States showed a significantly higher proportion of TB caused by M. bovis for HIV co-infected TB patients (Table 4). For studies from the USA, the relative risk for an infection with M. bovis among TB patients was 2.6–8.3 times higher in HIV–co-infected patients than in HIV-negative patients. No significant association between M. bovis infection and HIV status was identified in surveys in Africa or other countries of the Americas (Table 4).
Naturally, the occurrence of zoonotic TB is greatly dependent on the presence of TB in cattle. Information on the global distribution and prevalence of bovine TB is scarce, but available data suggest that TB in cattle is prevalent in virtually all major livestock-producing countries of the developing world and Africa, specifically (2,3,7). Disease control in cattle is largely absent in these regions. Consequently, the majority of the human population is at risk for exposure to bovine TB; and globally, the occurrence of zoonotic TB likely mirrors TB prevalence in cattle.
Our systematic literature search on the occurrence of zoonotic TB provided no data for the WHO region of Southeast Asia, including major cattle producing middle- and low-income countries (e.g., India, Bangladesh, Pakistan, Myanmar, Indonesia) (Technical Appendix 1 [PDF - 233 KB - 4 pages]) (33). Moreover, except for Europe, data were acquired for few countries of the regions represented in this analysis (Table 1) with some, in terms of livestock production, particularly relevant countries missing (e.g., Canada, Kenya, Russia, South Africa, Sudan, and Turkey) (33). Nationwide surveillance data were almost exclusively available for high-income countries that have programs in place for bovine TB control and regular milk pasteurization (Table 1). Although ample data were obtained for many low-risk, high-income countries, the lack of nationwide surveys in potential high-risk settings precluded a credible estimation of the global occurrence of zoonotic TB.
Recorded incidence rates for zoonotic TB in Europe, the United States, Australia, and New Zealand were consistently below 1/100,000 population/year (Technical Appendix 2 [PDF - 233 KB - 4 pages]). Incidence rates were unavailable for other countries. However, a crude estimate could be obtained by multiplying the observed country-specific median proportion of zoonotic TB by the respective overall TB incidence rates. This suggested incidence rates of zoonotic TB of ≈1/100,000 population/year or lower for all countries outside Africa included in this survey, except for the Republic of Djibouti that reported ≈4 zoonotic TB cases/100,000 population/year.
Africa is assumed to bear the highest consequences of zoonotic TB worldwide because of the frequent and concurrent presence of multiple risk factors (2,3,7). This is supported by the highest reported median proportions of TB caused by M. bovis in connection with the worldwide highest overall TB incidence rates (Figure 2). Given an observed median proportion of zoonotic TB of 2.8% and the continental average overall incidence of TB of 264/100,000 population/year (Figure 2), an incidence rate of 7 zoonotic TB cases/100,000 population/year could be estimated (≈20 times lower than the global overall TB incidence rate) (1). Presumably, this is an overestimate as high-risk livestock producing countries of Africa (e.g., Ethiopia, Madagascar, Nigeria, and Tanzania) were overrepresented in this analysis (33) and because studies reporting the presence of zoonotic TB can be expected to be overrepresented among the surveys included (see limitations of the study below). Together, this suggests a low incidence of zoonotic TB in Africa.
Individual studies from various regions reported high proportions of zoonotic TB for specific population groups and settings (Figures 3–6). For example, in the Hispanic community in the United States, zoonotic TB appeared to be a considerable proportion of all TB cases (Table 3) and was associated with the consumption of unpasteurized cheese from Mexico (8–12). The highest median proportions for TB caused by M. bovis were observed in countries in Africa: Ethiopia, Nigeria, and Tanzania (Figure 3). However, the specific populations affected and risk factors of zoonotic TB in these settings remain largely elusive. The highest proportions of zoonotic TB in Africa were reported in studies investigating cases of extrapulmonary TB (Table 2). For example, 9 of the 11 studies reporting proportions of zoonotic TB >10% included cases of extrapulmonary TB, and 4 of the 15 studies reporting a proportion of <3.3% extrapulmonary TB cases were included (Table 2). This may mirror a widely stated association of zoonotic TB with extrapulmonary disease, perhaps reflecting the consumption of contaminated animal products as one of the main drivers of zoonotic TB (2,3,7). It has been postulated that pastoralist and rural communities would be at greatest risk for zoonotic TB (2,3,7), but the lack of data for these population groups prevents confirmation of this assumption. Collected individual studies reporting high proportions of TB caused by M. bovis suggest pockets of zoonotic transmission of TB for specific population groups and settings.
Outside Africa, large proportions of M. bovis infections among TB case-patients have been found mostly in low-TB incidence settings such as Mexico. In Cyprus, Iceland, and Malta, proportions of TB caused by M. bovis of >10% were observed (Figure 5); however, these countries, nationwide, reported <20 human TB cases in the respective years. Similarly, a study in San Diego County, California, USA, showed an overall decreasing incidence of human TB while the incidence of zoonotic TB and therefore also the relative proportion of zoonotic TB has steadily increased (9,12). This suggests that commonly applied control efforts targeting M. tuberculosis transmission have little effect on the occurrence of zoonotic TB and probably reflects the distinct drivers of M. tuberculosis and zoonotic TB infection (e.g., aerosol transmission vs. foodborne infection) (2,3). Similarly, differences in the epidemiology of zoonotic TB are likely to exist between different regions. This could be mirrored by the association of zoonotic TB with HIV in the United States, but not in other areas included in this analysis (Table 4). Ascertaining the factors contributing to an association between HIV and zoonotic TB in some regions will require more in-depth research, thus eliminating potential confounders such as socioeconomic status, education level, national origin, and other factors.
The current study is affected by several biases. The sensitivity of this systematic literature review was affected by the selection of eligible reports and data extraction by a single operator. Also, only reports available online and written in English, French, German, Spanish, or Portuguese were included. Selected reports are biased toward surveys which identified or aimed to identify TB cases caused by M. bovis, possibly resulting in an overestimation of the proportion of zoonotic TB cases. Data from low-income countries included in this study were rarely comparable and not representative of the respective nationwide populations. Nonetheless, it seems unlikely that our conclusions were fundamentally affected by these biases. Lastly, our results are influenced by the technical constraints of the studies included. Specifically, biochemical methods may be relatively unreliable for the identification of M. bovis or M. caprae strains and routine culture methods for M. tuberculosis are suboptimal to detect strains of M. bovis (2,3). Thus, TB cases caused by M. bovis may be systematically underreported.
Reports published after the completion of this systematic review revealed information from countries not covered by this study. A study from Bangladesh analyzed isolates from 350 TB patients but did not identify any infections by M. bovis (34). In a study from Bamako, Mali, 0.8% of TB cases analyzed were caused by M. bovis (35). In Turkey and the West Bank, Palestine, respectively, 5.3% and 6.5% of clinical TB cases analyzed were caused by M. bovis (36,37); however, zoonotic TB can be considered rare in these areas, given the low overall incidence rates of TB of 28 and 0.7/100,000 population/year (1,38). Together, available data suggest a minor global importance of zoonotic TB. However, pockets of more frequent zoonotic transmission of TB seem to be present in certain population groups. More research is needed to identify the main transmission drivers in these areas.
Dr Müller is affiliated with the Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa, and the Swiss Tropical and Public Health Institute, Basel, Switzerland, which is associated with the University of Basel. His primary research focuses on various aspects of the molecular epidemiology of TB in resource-limited regions.
We thank Sebastien Gagneux for his critical comments on the manuscript.
This work was partially funded by WHO. B.M. and J.H., respectively, received financial support from the Novartis Foundation and from EU grant FP7-221948 ICONZ.
- World Health Organization. Global tuberculosis control: WHO Report 2011. Geneva: The Organization; 2011.
- Cosivi O, Grange JM, Daborn CJ, Raviglione MC, Fujikura T, Cousins D, Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis. 1998;4:59–70 and.
- Ayele WY, Neill SD, Zinsstag J, Weiss MG, Pavlik I. Bovine tuberculosis: an old disease but a new threat to Africa. Int J Tuberc Lung Dis. 2004;8:924–37 .
- Murphree R, Warkentin JV, Dunn JR, Schaffner W, Jones TF. Elephant-to-human transmission of tuberculosis, 2009. Emerg Infect Dis. 2011;17:366–71 and.
- Kiers A, Klarenbeek A, Mendelts B, Van Soolingen D, Koëter G. Transmission of Mycobacterium pinnipedii to humans in a zoo with marine mammals. Int J Tuberc Lung Dis. 2008;12:1469–73 .
- Torgerson PR, Torgerson DJ. Public health and bovine tuberculosis: what’s all the fuss about? Trends Microbiol. 2010;18:67–72 and.
- Michel AL, Muller B, Van Helden PD. Mycobacterium bovis at the animal-human interface: a problem, or not? Vet Microbiol. 2010;140:371–81 and.
- Hlavsa MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, Morlock GP, Human tuberculosis due to Mycobacterium bovis in the United States, 1995–2005. Clin Infect Dis. 2008;47:168–75 and.
- Rodwell TC, Moore M, Moser KS, Brodine SK, Strathdee SA. Tuberculosis from Mycobacterium bovis in binational communities, United States. Emerg Infect Dis. 2008;14:909–16 and.
- LoBue PA, Moser KS. Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994–2003. Int J Tuberc Lung Dis. 2005;9:333–8 .
- Centers for Disease Control and Prevention. Human tuberculosis caused by Mycobacterium bovis—New York City, 2001–2004. MMWR Morb Mortal Wkly Rep. 2005;54:605–8 .
- LoBue PA, Betacourt W, Peter C, Moser KS. Epidemiology of Mycobacterium bovis disease in San Diego County, 1994–2000. Int J Tuberc Lung Dis. 2003;7:180–5 .
- Shitaye JE, Tsegaye W, Pavlik I. Bovine tuberculosis infection in animal and human populations in Ethiopia: A review. Vet Med (Praha). 2007;52:317–32 [cited 2012 Feb 1]. http://www.vri.cz/docs/vetmed/52-8-317.pdf
- Fetene T, Kebede N, Alem G. Tuberculosis infection in animal and human populations in three districts of Western Gojam, Ethiopia. Zoonoses Public Health. 2011;58:47–53 and.
- Alemayehu R, Girmay M, Gobena A. Bovine tuberculosis is more prevalent in cattle owned by farmers with active tuberculosis in central Ethiopia. Vet J. 2008;178:119–25 and.
- Mawak J, Gomwalk N, Bello C, Kandakai-Olukemi Y. Human pulmonary infections with bovine and environment (atypical) mycobacteria in Jos, Nigeria. Ghana Med J. 2006;40:132–6 .
- World Health Organization. Report of the WHO working group on zoonotic tuberculosis (Mycobacterium bovis), with the participation of the FAO; 14 June, 1994; Mainz, Germany. Geneva: The Organization. 1994;1–45 [cited 2012 Feb 1]. http://whqlibdoc.who.int/hq/1994/WHO_CDS_VPH_94.137.pdf
- Mfinanga SG, Morkve O, Kazwala RR, Cleaveland S, Sharp MJ, Kunda J, Mycobacterial adenitis: role of Mycobacterium bovis, non-tuberculous mycobacteria, HIV infection, and risk factors in Arusha, Tanzania. East Afr Med J. 2004;81:171–8 and.
- Kazwala RR, Daborn CJ, Sharp JM, Kambarage DM, Jiwa SF, Mbembati NA. Isolation of Mycobacterium bovis from human cases of cervical adenitis in Tanzania: a cause for concern? Int J Tuberc Lung Dis. 2001;5:87–91 .
- Cicero R, Olivera H, Hernandez-Solis A, Ramirez-Casanova E, Escobar-Gutierrez A. Frequency of Mycobacterium bovis as an etiologic agent in extrapulmonary tuberculosis in HIV-positive and -negative Mexican patients. Eur J Clin Microbiol Infect Dis. 2009;28:455–60 and.
- Ordóñez PT, Milian SF, Santillán FMA, Ramírez CIC. Aislamiento e identificación de Mycobacterium bovis a partir de muestras de expectoración de pacientes humanos con problemas respiratorios crónicos [in Spanish with English translation]. Veterinaria (Mex). 1999;30:227–9 [cited 2012 Feb 1]. http://www.redalyc.org/pdf/423/42330303.pdf
- Pérez-Guerrero L, Milian-Suazo F, Arriga-Díaz C, Romero-Torres C, Escartin-Chávez M. Epidemiología molecular de las tuberculosis bovina y humana en una zona endémica de Quarétaro, México. Salud Publica Mex. 2008;50:286–91 and.
- Prodinger WM, Eigentler A, Allerberger F, Schonbauer M, Glawischnig W. Infection of red deer, cattle, and humans with Mycobacterium bovis subsp. caprae in western Austria. J Clin Microbiol. 2002;40:2270–2 and.
- Kubica T, Rusch-Gerdes S, Niemann S. Mycobacterium bovis subsp. caprae caused one-third of human M. bovis-associated tuberculosis cases reported in Germany between 1999 and 2001. J Clin Microbiol. 2003;41:3070–7 and.
- Neonakis IK, Gitti Z, Petinaki E, Maraki S, Spandidos DA. Evaluation of the GenoType MTBC assay for differentiating 120 clinical Mycobacterium tuberculosis complex isolates. Eur J Clin Microbiol Infect Dis. 2007;26:151–2 and.
- Rodríguez E, Sanchez LP, Perez S, Herrera L, Jimenez MS, Samper S, Human tuberculosis due to Mycobacterium bovis and M. caprae in Spain, 2004–2007. Int J Tuberc Lung Dis. 2009;13:1536–41 .
- Ammon A, Makela P. Integrated data collection on zoonoses in the European Union, from animals to humans, and the analyses of the data. Int J Food Microbiol. 2010;139(Suppl 1):S43–7 and.
- Zink AR, Nerlich AG. Molecular strain identification of the Mycobacterium tuberculosis complex in archival tissue samples. J Clin Pathol. 2004;57:1185–92 and.
- Samper S, Iglesias MJ, Rabanaque MJ, Gomez LI, Lafoz MC, Jimenez MS, Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain. J Clin Microbiol. 2005;43:1220–7 and.
- Abbadi S, El HG, Gomaa N, Cooksey R. Strain differentiation of Mycobacterium tuberculosis complex isolated from sputum of pulmonary tuberculosis patients. Int J Infect Dis. 2009;13:236–42 and.
- Koeck JL, Bernatas JJ, Gerome P, Fabre M, Houmed A, Herve V, [Epidemiology of resistance to antituberculosis drugs in Mycobacterium tuberculosis complex strains isolated from adenopathies in Djibouti. Prospective study carried out in 1999]. Med Trop (Mars). 2002;62:70–2 .
- de Kantor IN, Ambroggi M, Poggi S, Morcillo N, Da Silva Telles MA, Osorio RM, Human Mycobacterium bovis infection in ten Latin American countries. Tuberculosis (Edinb). 2008;88:358–65 and.
- Wint GRW, Robinson TP. Gridded livestock of the world 2007. Rome: Food and Agriculture Organization; 2007. p. 1–131.
- Nakajima C, Rahim Z, Fukushima Y, Sugawara I, Van der Zanden AG, Tamaru A, Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR. BMC Infect Dis. 2010;10:118 and.
- Traore B, Diarra B, Dembele BPP, Somboro AM, Hammond AS, Siddiqui S, Molecular strain typing of Mycobacterium tuberculosis complex in Bamako, Mali. Int J Tuberc Lung Dis. 2012;16:911–6 and.
- Bayraktar B, Bulut E, Bariş AB, Toksoy B, Dalgic N, Celikkan C, Species distribution of the Mycobacterium tuberculosis complex in clinical isolates from 2007 to 2010 in Turkey: a prospective study. J Clin Microbiol. 2011;49:3837–41 and.
- Ereqat S, Nasereddin A, Azmi K, Abdeen Z, Greenblatt CL, Spigelman M, Genetic characterization of Mycobacterium tuberculosis in the West Bank, Palestinian Territories. BMC Res Notes. 2012;5:270 and.
- Palestinian Health Information Center. Health Annual Report Palestine 2010 [Internet]. Ministry of Health; 2011 Apr [cited 2012 Feb 1]. http://www.moh.ps/attach/297.pdf
- Figure 2. . Proportion of zoonotic tuberculosis (TB) among all TB cases (A) and estimated overall TB incidence (B) stratified by World Health Organization (WHO) region. Overall TB incidence rates estimated...
- Figure 3. . Proportion of zoonotic tuberculosis (TB) among all TB cases stratified by country: Africa. x-axis values are median proportions. Each circle represents a study with the circle diameter being...
- Figure 4. . Proportion of zoonotic tuberculosis (TB) among all TB cases stratified by country: Americas. x-axis values are median proportions. Each circle represents a study with the circle diameter being...
- Figure 5. . Proportion of zoonotic tuberculosis (TB) among all TB cases stratified by country: Europe. x-axis values are median proportions. Each circle represents a study with the circle diameter being...
- Figure 6. . Proportion of zoonotic tuberculosis (TB) among all TB cases stratified by country: A) Eastern Mediterranean; B) Western Pacific. x-axis values are median proportions. Each circle represents a study...
- Table 1. Number of countries within World Health Organization regions for which the respective data on zoonotic Mycobacterium bovis–induced TB in humans was obtained
- Table 2. Overview of selected reports from Africa on zoonotic Mycobacterium bovis–induced TB in humans
- Table 3. Selected reports from the United States on zoonotic Mycobacterium bovis-induced TB in humans
- Table 4. Available data on zoonotic Mycobacterium bovis-induced TB in humans, stratified by HIV-positive and -negative populations
- Technical Appendix 1. . All searched bibliographic databases; search terms used to identify potentially relevant reports; member states of the World Health Organization regions; and heat map of the number of... 233 KB
- Technical Appendix 2. . Database of all identified 1,203 potentially relevant reports; core dataset extracted from eligible records including data on disease frequency and mortality; and variable names used for the... 996 KB
Please use the form below to submit correspondence to the authors or contact them at the following address:
Corresponding address: Borna Müller, Swiss Tropical and Public Health Institute, Medical Parisitology and Infection Biology, Socinstrasse 57 , Basel 4002, Switzerland
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: May 21, 2013
- Page last updated: May 21, 2013
- Page last reviewed: May 21, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)